What's the development stage of the Luminostics platform?
Our diagnostics platform is de-risked and scale-ready with excellent analytical and/or clinical validation data on tests for influenza A/B, chlamydia, gonorrhea, HIV, and herpes. Our company’s long-term mission is to empower consumers with rapid OTC self-diagnostics and associated telehealth services for a wide variety of applications beginning with infectious diseases. At present, we have put all projects on hold to quickly develop and launch products for rapid COVID-19 diagnostics.
Does Luminostics partner with others to develop products?
We have ongoing collaborations with commercial, government, and non-profit partners to develop a portfolio of diagnostic products that leverage the unique advantages of our technology platform.We occasionally fund academic research laboratories to co-develop assays for our platform or perform blue-sky research. When we fund academic partners, we support indirect costs of up to 10% of the total direct budget of the project. Higher indirect cost rates will not be accepted.